Brain-Computer Interface (BCI) competition is intensifying as Neuralink rival Synchron closes a mass...
The AMW Read
Synchron updates the player map in the BCI/Healthcare segment with a significant $305M round and $1B valuation, though it falls short of the $500M cross.§D threshold for a 'mega-round' tag.
NoveltySignificance
Healthcare & Bio · Player MapCapital Cycles
Brain-Computer Interface (BCI) competition is intensifying as Neuralink rival Synchron closes a massive $305 million Series D round, valuing the company at approximately $1 billion. This funding, which includes a $54 million investment from the Australian government's National Reconstruction Fund, validates Synchron's less-invasive Stentrode technology over Neuralink's high-risk surgical approach. The capital injection positions Synchron to push into large-scale clinical trials for conditions like stroke and MS, accelerating the commercialization timeline for AI-driven neurological treatments. The race for human augmentation is officially a well-funded, two-horse battle.
